TrainingDoyens

Toll Free: +1-888-300-8494 Login/Sign up

  • DigiMeet
    • About DigiMeet
    • Benefits
    • Upcoming DigiMeets
  • Webinars
    • Recorded Webinars
    • Webinar Packs
    • CEU Approved Webinars
    • Best Sellers
    • Training Catalogue
  • Annual Membership
  • Speakers
    • Our Experts
    • Speaking Opportunity
    • Ask a Question
    • Suggest a Topic
  • Corporate Offers
    • Corporate Training
    • Digital Marketing
    • Sponsored Webinar
    • GMP Consulting
    • IT Consulting
  • About Us
    • Company
    • Clients
    • Testimonials
    • Blog
    • Free Resources
    • Contact Us

David R. Dills

David R. Dills
Global Regulatory Affairs & Compliance Consultant

Years of Experience: 26+ years

Areas of Expertise: Regulatory Affairs, Compliance and Quality Systems

David R. Dills, Global Regulatory Affairs & Compliance Consultant, Interim President, currently provides global regulatory affairs, compliance and quality consultative services for early-stage and established Class I/II/III medical device, including combination products, In Vitro Diagnostics, nutraceuticals/supplements, cosmetics and biopharmaceutical manufacturers in multiple medical specialties and therapeutic areas on the global landscape, and has an accomplished record with more than 26 years of experience in the areas of Regulatory Affairs, Compliance and Quality Systems. He has been previously employed, with increasing responsibilities by medical device manufacturers and consultancies, including a globally recognized CRO and has worked directly with manufacturers engaged in compliance remediation activities and services involving consent decrees, CIA’s, warning letters,483 observations, and customer generated compliance events, and prepares for and conducts QS and regulatory audits. He is currently acting and interim President at NovaQual LLC. 

He has been directly involved with constructing, reviewing, and/ or remediating regulatory submissions, including 510(k), PMA, IDE applications, IND, BLA and NDA submissions, preparing responses to AI’s/deficiency letters, Supplements, Amendments, acting U.S. Agent, works closely with the key stakeholders and Agency/Center Reviewers regarding submission meetings and negotiations; clinical affairs and study submissions; and provides regulatory submissions and post-market project leadership and guidance covering different therapeutic and medical specialties based on classification. 

Mr. Dills has a strong background in the interpretation and applicability of FDA regulations, including 21 CFR 210/211, 820 QSR/cGMP, Quality System implementation and compliance requirements, GxP training, leads and directs activities for the registration and approval process and working with Agencies in Asia Pacific, EU and The Americas, including but not limited to FDA, European Medicines Agency–EMA, MHRH, ANVISA, PMDA, MOH, SFDA, TGA, and Health Canada; and defining and executing regulatory compliance, risk mitigation and remediation strategies in response to inspection findings. Additional activities include Pre-FDA Facility Inspections, Mock Audits/Due diligence and assessing state of readiness for Pre-approval inspection (PAI/PMA), proof of management oversight, facilitate and direct efforts for remediation planning and monitoring, and assessment of the critical sub-systems, records and document controls; and strives for reduction of regulatory compliance risk for companies. 

Directs and leads efforts for PM support and consultative services on behalf of manufacturers and subcontracted by third-party consultancies and provides services involving all phases of the product development, submission, and commercialization process from premarketing to post marketing; retained as U.S. Agent for international pharma and device clients; conducting supplier and QS audits/assessments; UDI compliance strategies; establishment registration and listing; Agency inspection readiness preparation and remediation; preparing Agency responses due to enforcement actions; conducting GxP audits and preparing CAP/remediation plans; compliance engineering support; support and/or lead efforts regarding Adverse Event, MDR, Incident Reporting, Post marketing Surveillance and Vigilance Reporting; clinical affairs, establish and/or remediate Quality Management and documentation systems for GxP compliance; preparation for ISO13485 registration and CEMark; and multi-country product registrations and licensing.

PopularUpcoming Webinars

view all upcoming webinars

Webinars by this Keynote Speaker

Upcoming Webinars Recorded Webinars
search FDA's New Import Program for 2018 – Are you prepared?

FDA's New Import Program for 2018 – Are you prepared? Life Sciences

  David R. Dills
Purchase
  • < previous
  • next >
Showing 1-1 of 1 Webinar
Training Doyens
26468 E Walker Dr,Aurora,
Colorado 80016-6104
Email: support@trainingdoyens.com
Toll Free:+1-888-300-8494
Tel: +1-720-996-1616
Fax: +1-888-909-1882

Our support team is available from
09:30 AM - 6:30PM Eastern
Monday to Friday


Connect with Us
QUICKLINKS
  • Webinars
  • About Us
  • Speakers
  • Terms & Conditions
  • Privacy Policy
  • Refund & Cancellation Policy
PAYMENT METHODS

We accept the following major credit/debit cards

payment options
GET HELP
  • Feedback
  • Support
  • FAQs
  • Site Map
  • Sponsorship and Advertising
  • Subscribe Newsletter
  • Unsubscribe
McAfee SECURE sites help keep you safe from identity theft, credit card fraud, spyware, spam, viruses and online scams
GET IN TOUCH WITH US

Copyright © 2017-2020 TrainingDoyens. All rights reserved.